摘要
目的研究卵巢癌患者行血清癌抗原125(CA125)联合血清铁蛋白(SF)诊断的效果。方法选取80例卵巢癌患者为观察组,经病理学诊断卵巢恶性肿瘤40例,作为观察1组,卵巢良性肿瘤40例,作为观察2组;另择取本院健康普查80例女性为对照组。观察组与对照组均行CA125联合SF诊断,比较诊断结果。结果观察1组CA125、SF水平高于观察2组、对照组,且观察2组高于对照组,差异有统计学意义(P<0.05);观察1组联合检测阳性率(95.00%)高于观察2组(30.00%)、对照组(2.50%),观察2组高于对照组,差异有统计学意义(P<0.05)。联合检测阳性率高于单项检测,差异有统计学意义(P<0.05)。结论CA125+SF检测可提高卵巢癌的阳性率,可为临床诊疗疾病提供参考。
Objective To study the diagnostic effect of serum cancer antigen 125(CA125)+serum ferritin(SF)in patients with ovarian cancer.Methods 80 patients with ovarian cancer were selected as the observation group.There were 40 cases of malignant ovarian tumors diagnosed by pathology as observation group 1,and 40 cases of benign ovarian tumors as observation group 2.Another 80 women from the hospital health survey were selected as the control group.CA125+SF diagnosis was performed in the observation group and the reference group,and the final diagnosis results were analyzed.Results The CA125 and SF values of observation group 1 were higher than those of observation group 2 and reference group,and observation group 2 was higher than the reference group,and the differences were statistically significant(P<0.05).The positive rate of combined detection in observation group 1(95.00%)was higher than that in observation group 2(30.00%)and reference group(2.50%),and the difference was statistically significant(P<0.05).The positive rate of combined detection was higher than that of single detection,the difference was statistically significant(P<0.05).Conclusion CA125+SF detection can improve the positive rate of ovarian cancer,which can provide reference for clinical diagnosis and treatment.
作者
赵晓婷
Zhao Xiaoting(Department of Gynecology,The Second People’s Hospital of Anhui Province,Hefei 233000,China)
出处
《实用妇科内分泌电子杂志》
2021年第25期15-17,共3页
Electronic Journal of Practical Gynecological Endocrinology
